



1/7


Fig. 1

Best Available Copy

2 / 7

Fig. 2



Best Available Copy

Fig. 3

Best Available Copy


Fig. 4**a**

80	A T E I P -	TY G T D E W E Q W W N A F N E - - - E - N L F C S E E M P	SV40
80	- - E V P -	TY G T E E W E S W W S S F N E K W D E - D L F C H E D M	BKV
80	S - E V P -	TY G T D E W E S W W N T P N E K W D E - D L F C H E E	JCV
40	- - - - -	G T S Q W E Q W W E E R N Q ' G F D E Q D L H C D E E	BPV
80	L - Q I P - S Y G T P E W D E W W K E F N K D F - - -	D L F C N E A F D	Kilham
100	D D Y W S F S Y G S K Y F T R E W N D F F R K W D - - - - - - - - - P	PyV	


b**c**

Best Available Copy


5 / 7

a**Fig. 5****b**

dl89-97





T

**c**

40 50 100

40 50 100

40 50 100




securin

 β -actin

U2OS


U2OS/
dl89-97

U2OS/T

d


Best Available C

6 / 7

Fig. 6

7 / 7

Fig. 7



Best Available Copy